Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes
Clearside Biomedical (Nasdaq: CLSD) announced positive topline results from its ODYSSEY Phase 2b trial of CLS-AX for treating wet AMD. The trial achieved all primary and secondary outcomes, demonstrating:
1. Stable visual acuity and anatomical control over 9 months 2. Positive safety profile with no ocular or treatment-related serious adverse events 3. 67% of CLS-AX participants not requiring additional treatment up to 6 months 4. 84% reduction in treatment burden over 6 months
CLS-AX, delivered via Clearside's proprietary SCS Microinjector®, showed potential for flexible maintenance dosing between 3 to 6 months. The company plans to advance the program into Phase 3 development based on these encouraging results.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.